Genes and Hope: The Promise of Personalized Treatment for Mesothelioma

ByHolly Zink
Genes and Hope: The Promise of Personalized Mesothelioma Treatments

A new study used advanced technology to understand the genetic details of mesothelioma. New results are pointing to potential ways to personalize treatment for this rare and aggressive cancer.

Mesothelioma starts in the thin lining around our organs. It is caused by exposure to asbestos. This cancer is known for being hard to treat and having few options for therapy. But recent research brings some hope.

Exploring Mesothelioma with Sequencing

Sequencing technology has been a big help in studying mesothelioma. It helps us understand its genetic makeup. One important finding is that more than 20% of the time, there are genetic issues. These issues may affect crucial genes called tumor suppressors. Some of the most common mutated genes in mesothelioma are BAP1, CDKN2A, NF2, SETD2, and TP53.

While finding these genetic issues is a big step, turning this information into effective treatments is tough. Right now, there isn’t enough evidence to show that directly targeting these genetic problems with drugs works well. This creates a gap in developing personalized treatments for people with mesothelioma.

A Hopeful Approach with Personalized Medicine

A small number (1-2%) of mesothelioma cases have mutations in genes that encourage cancer growth (oncogenes). There are already drugs designed to target these specific mutations. This opens up the possibility of a more personalized treatment for mesothelioma. These patients might benefit from existing targeted therapies.

The main challenge in mesothelioma is linking genetic discoveries to practical treatment plans. As we dig deeper into understanding its genetic code, researchers are working on ways to create targeted therapies.

The ultimate goal is to use insights from these experiments to find new targets for drugs. And, they can make existing therapies better for each mesothelioma patient. Tailored treatments are based on the specific genetic details of each person’s tumor. Researchers are trying to improve outcomes and give more time to those dealing with this tough cancer.

Sequencing has changed how we see mesothelioma by revealing its complex genetic code. Even though there are challenges in turning this knowledge into effective treatments, the potential is big. Personalized treatment guided by sequencing give hope to people with mesothelioma. Ongoing research and collaboration in the scientific community are key to finding breakthroughs that can make a difference in the fight against this difficult disease.

Source:

Cerbone, Luigi, Sara Orecchia, Pietro Bertino, Sara Delfanti, Antonina Maria de Angelis, and Federica Grosso. “Clinical Next Generation Sequencing Application in Mesothelioma: Finding a Golden Needle in the Haystack.” CANCERS 15, no. 24 (December 2023): 5716. https://doi.org/10.3390/cancers15245716.

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    ByAlex Strauss

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…

  • | |

    Value of Mesothelioma Surgery Challenged for Healthy Patients

    ByAlex Strauss

    New research conducted in Italy and presented at the 15th World Conference on Lung Cancer in Sydney, Australia suggests that mesothelioma surgery – no matter what kind – may not offer a survival advantage over medical management for the healthiest of patients. Mesothelioma is a rare but aggressive malignancy that is highly resistant to standard cancer treatments. The two types of mesothelioma surgery considered to be options for people with resectable cancer are pleurectomy decortication (P/D) or extrapleural pneumonectomy (EPP). While EPP is more radical than P/D because it involves removing a lung, both carry a heavy risk of complications and, according to the Italian researchers, may not be of value for certain patients. The study reviewed data from 1,365…